Cargando…

Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF-β Dependent Hepatic Stellate Cell Activation and Liver Fibrosis

BACKGROUND & AIMS: Transdifferentiation of hepatic stellate cells (HSCs) into myofibroblasts is a key event in the pathogenesis of liver fibrosis. Transforming growth factor β (TGF-β) and platelet-derived growth factor (PDGF) are canonical HSC activators after liver injury. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Mateos, Rosa, De Assuncao, Thiago M., Arab, Juan Pablo, Jalan-Sakrikar, Nidhi, Yaqoob, Usman, Greuter, Thomas, Verma, Vikas K., Mathison, Angela J., Cao, Sheng, Lomberk, Gwen, Mathurin, Philippe, Urrutia, Raul, Huebert, Robert C., Shah, Vijay H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282644/
https://www.ncbi.nlm.nih.gov/pubmed/30539787
http://dx.doi.org/10.1016/j.jcmgh.2018.09.005
_version_ 1783379038844223488
author Martin-Mateos, Rosa
De Assuncao, Thiago M.
Arab, Juan Pablo
Jalan-Sakrikar, Nidhi
Yaqoob, Usman
Greuter, Thomas
Verma, Vikas K.
Mathison, Angela J.
Cao, Sheng
Lomberk, Gwen
Mathurin, Philippe
Urrutia, Raul
Huebert, Robert C.
Shah, Vijay H.
author_facet Martin-Mateos, Rosa
De Assuncao, Thiago M.
Arab, Juan Pablo
Jalan-Sakrikar, Nidhi
Yaqoob, Usman
Greuter, Thomas
Verma, Vikas K.
Mathison, Angela J.
Cao, Sheng
Lomberk, Gwen
Mathurin, Philippe
Urrutia, Raul
Huebert, Robert C.
Shah, Vijay H.
author_sort Martin-Mateos, Rosa
collection PubMed
description BACKGROUND & AIMS: Transdifferentiation of hepatic stellate cells (HSCs) into myofibroblasts is a key event in the pathogenesis of liver fibrosis. Transforming growth factor β (TGF-β) and platelet-derived growth factor (PDGF) are canonical HSC activators after liver injury. The aim of this study was to analyze the epigenetic modulators that differentially control TGF-β and PDGF signaling pathways. METHODS: We performed a transcriptomic comparison of HSCs treated with TGF-β or PDGF-BB using RNA sequencing. Among the targets that distinguish these 2 pathways, we focused on the histone methyltransferase class of epigenetic modulators. RESULTS: Enhancer of zeste homolog 2 (EZH2) was expressed differentially, showing significant up-regulation in HSCs activated with TGF-β but not with PDGF-BB. Indeed, EZH2 inhibition using either a pharmacologic (GSK-503) or a genetic (small interfering RNA) approach caused a significant attenuation of TGF-β–induced fibronectin, collagen 1α1, and α-smooth muscle actin, both at messenger RNA and protein levels. Conversely, adenoviral overexpression of EZH2 in HSCs resulted in a significant stimulation of fibronectin protein and messenger RNA levels in TGF-β–treated cells. Finally, we conducted in vivo experiments with mice chronically treated with carbon tetrachloride or bile duct ligation. Administration of GSK-503 to mice receiving either carbon tetrachloride or bile duct ligation led to attenuated fibrosis as assessed by Trichrome and Sirius red stains, hydroxyproline, and α-smooth muscle actin/collagen protein assays. CONCLUSIONS: TGF-β and PDGF share redundant and distinct transcriptomic targets, with the former predominating in HSC activation. The EZH2 histone methyltransferase is preferentially involved in the TGF-β as opposed to the PDGF signaling pathway. Inhibition of EZH2 attenuates fibrogenic gene transcription in TGF-β–treated HSCs and reduces liver fibrosis in vivo. The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE119606 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119606)
format Online
Article
Text
id pubmed-6282644
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-62826442018-12-13 Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF-β Dependent Hepatic Stellate Cell Activation and Liver Fibrosis Martin-Mateos, Rosa De Assuncao, Thiago M. Arab, Juan Pablo Jalan-Sakrikar, Nidhi Yaqoob, Usman Greuter, Thomas Verma, Vikas K. Mathison, Angela J. Cao, Sheng Lomberk, Gwen Mathurin, Philippe Urrutia, Raul Huebert, Robert C. Shah, Vijay H. Cell Mol Gastroenterol Hepatol Original Research BACKGROUND & AIMS: Transdifferentiation of hepatic stellate cells (HSCs) into myofibroblasts is a key event in the pathogenesis of liver fibrosis. Transforming growth factor β (TGF-β) and platelet-derived growth factor (PDGF) are canonical HSC activators after liver injury. The aim of this study was to analyze the epigenetic modulators that differentially control TGF-β and PDGF signaling pathways. METHODS: We performed a transcriptomic comparison of HSCs treated with TGF-β or PDGF-BB using RNA sequencing. Among the targets that distinguish these 2 pathways, we focused on the histone methyltransferase class of epigenetic modulators. RESULTS: Enhancer of zeste homolog 2 (EZH2) was expressed differentially, showing significant up-regulation in HSCs activated with TGF-β but not with PDGF-BB. Indeed, EZH2 inhibition using either a pharmacologic (GSK-503) or a genetic (small interfering RNA) approach caused a significant attenuation of TGF-β–induced fibronectin, collagen 1α1, and α-smooth muscle actin, both at messenger RNA and protein levels. Conversely, adenoviral overexpression of EZH2 in HSCs resulted in a significant stimulation of fibronectin protein and messenger RNA levels in TGF-β–treated cells. Finally, we conducted in vivo experiments with mice chronically treated with carbon tetrachloride or bile duct ligation. Administration of GSK-503 to mice receiving either carbon tetrachloride or bile duct ligation led to attenuated fibrosis as assessed by Trichrome and Sirius red stains, hydroxyproline, and α-smooth muscle actin/collagen protein assays. CONCLUSIONS: TGF-β and PDGF share redundant and distinct transcriptomic targets, with the former predominating in HSC activation. The EZH2 histone methyltransferase is preferentially involved in the TGF-β as opposed to the PDGF signaling pathway. Inhibition of EZH2 attenuates fibrogenic gene transcription in TGF-β–treated HSCs and reduces liver fibrosis in vivo. The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE119606 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119606) Elsevier 2018-09-15 /pmc/articles/PMC6282644/ /pubmed/30539787 http://dx.doi.org/10.1016/j.jcmgh.2018.09.005 Text en © 2019 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Research
Martin-Mateos, Rosa
De Assuncao, Thiago M.
Arab, Juan Pablo
Jalan-Sakrikar, Nidhi
Yaqoob, Usman
Greuter, Thomas
Verma, Vikas K.
Mathison, Angela J.
Cao, Sheng
Lomberk, Gwen
Mathurin, Philippe
Urrutia, Raul
Huebert, Robert C.
Shah, Vijay H.
Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF-β Dependent Hepatic Stellate Cell Activation and Liver Fibrosis
title Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF-β Dependent Hepatic Stellate Cell Activation and Liver Fibrosis
title_full Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF-β Dependent Hepatic Stellate Cell Activation and Liver Fibrosis
title_fullStr Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF-β Dependent Hepatic Stellate Cell Activation and Liver Fibrosis
title_full_unstemmed Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF-β Dependent Hepatic Stellate Cell Activation and Liver Fibrosis
title_short Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF-β Dependent Hepatic Stellate Cell Activation and Liver Fibrosis
title_sort enhancer of zeste homologue 2 inhibition attenuates tgf-β dependent hepatic stellate cell activation and liver fibrosis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282644/
https://www.ncbi.nlm.nih.gov/pubmed/30539787
http://dx.doi.org/10.1016/j.jcmgh.2018.09.005
work_keys_str_mv AT martinmateosrosa enhancerofzestehomologue2inhibitionattenuatestgfbdependenthepaticstellatecellactivationandliverfibrosis
AT deassuncaothiagom enhancerofzestehomologue2inhibitionattenuatestgfbdependenthepaticstellatecellactivationandliverfibrosis
AT arabjuanpablo enhancerofzestehomologue2inhibitionattenuatestgfbdependenthepaticstellatecellactivationandliverfibrosis
AT jalansakrikarnidhi enhancerofzestehomologue2inhibitionattenuatestgfbdependenthepaticstellatecellactivationandliverfibrosis
AT yaqoobusman enhancerofzestehomologue2inhibitionattenuatestgfbdependenthepaticstellatecellactivationandliverfibrosis
AT greuterthomas enhancerofzestehomologue2inhibitionattenuatestgfbdependenthepaticstellatecellactivationandliverfibrosis
AT vermavikask enhancerofzestehomologue2inhibitionattenuatestgfbdependenthepaticstellatecellactivationandliverfibrosis
AT mathisonangelaj enhancerofzestehomologue2inhibitionattenuatestgfbdependenthepaticstellatecellactivationandliverfibrosis
AT caosheng enhancerofzestehomologue2inhibitionattenuatestgfbdependenthepaticstellatecellactivationandliverfibrosis
AT lomberkgwen enhancerofzestehomologue2inhibitionattenuatestgfbdependenthepaticstellatecellactivationandliverfibrosis
AT mathurinphilippe enhancerofzestehomologue2inhibitionattenuatestgfbdependenthepaticstellatecellactivationandliverfibrosis
AT urrutiaraul enhancerofzestehomologue2inhibitionattenuatestgfbdependenthepaticstellatecellactivationandliverfibrosis
AT huebertrobertc enhancerofzestehomologue2inhibitionattenuatestgfbdependenthepaticstellatecellactivationandliverfibrosis
AT shahvijayh enhancerofzestehomologue2inhibitionattenuatestgfbdependenthepaticstellatecellactivationandliverfibrosis